XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Interim Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 6 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Mar. 31, 2023
Mar. 31, 2022
Operating expenses        
General and administrative $ 2,882,568 $ 2,915,158 $ 6,199,604 $ 5,982,109
Research and development 11,306,591 8,604,589 23,373,510 17,261,028
Total operating expenses 14,189,159 11,519,747 29,573,114 23,243,137
Operating loss (14,189,159) (11,519,747) (29,573,114) (23,243,137)
Other income (expenses)        
Grant income 25,000
Research and development incentive income 749,681 835,513 1,483,271 1,646,243
Interest income, net 1,465,221 7,578 2,732,839 12,488
Other financing expense (964,344) (964,344)
Foreign exchange (loss) gain (118,678) 268,645 247,305 324,008
Total other income, net 1,131,880 1,111,736 3,524,071 1,982,739
Net loss before provision for income taxes (13,057,279) (10,408,011) (26,049,043) (21,260,398)
Income tax expense, current (50,000) (29,800) (29,954) (59,780)
Net loss and comprehensive loss $ (13,107,279) $ (10,437,811) $ (26,078,997) $ (21,320,178)
Net Loss per share        
Basic and diluted $ (0.17) $ (0.14) $ (0.33) $ (0.28)
Weighted average number of shares outstanding        
Basic and diluted $ 78,304,363 $ 76,248,603 $ 78,138,940 $ 76,121,792